Global $18.3 Bn Atopic Dermatitis Drug Forecast and Market Analysis to 2027 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 20, 2019--
The “Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027” report has been added to ResearchAndMarkets.com’s offering.
The report “Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027”, provides key metrics for atopic dermatitis (Epidemiology, Market Size, Product Pipeline, Key Events, Competitive Analysis) in the seven major pharmaceutical markets (7MM) covered in this report-the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan-during the forecast period from 2017-2027.
Global sales in the atopic dermatitis market are expected to grow to $18.3B by 2027, at a Compound Annual Growth Rate (CAGR) of 11.1% from 2017-2027. It is estimated that sales of drugs in the atopic dermatitis market were approximately $6.4B in 2017 in the 7MM (United States, France, Germany, Italy, Spain, United Kingdom and Japan).
The US was the largest market, with approximately $5.1B in drug sales, which represented 80% of the total atopic dermatitis market. The 5EU market contributed $1.1B in sales and Japan contributed sales of $202M in 2017. It is forecasted that the US to grow to $13.6B, followed by 5EU (France, Germany, Italy, Spain, United Kingdom) and Japan.
Atopic dermatitis is a widespread chronic inflammatory skin condition that can affect patients of all ages and is the result of a complex interplay of environmental, immunological, genetic, and pharmacologic factors. The atopic dermatitis market has historically remained stagnant and the pipeline for drugs in late-stage development was lacking, but recent developments have reignited interest in the treatment of the disease, especially as the estimated drug-treated population may grow to 24,000,000 people over the next decade.
The atopic dermatitis pipeline has traditionally been focused on topical therapies, with Pfizer’s Eucrisa being the latest to be approved in December 2016. Until the launch of Regeneron/Sanofi’s Dupixent in March 2017, severe atopic dermatitis patients had to be prescribed systemic immunomodulators, which are associated with a slew of side effects. However, the arrival of Dupixent, a first-in-class monoclonal antibody (mAb), addressed the unmet needs of these severe patients. The pipeline mostly comprises systemic therapies targeting the moderate-to-severe population.
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global atopic dermatitis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global atopic dermatitis therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global atopic dermatitis therapeutics market from 2017-2027.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Atopic Dermatitis: Executive Summary
2.1 Atopic Dermatitis Market to Experience Strong Growth from 20172027
2.2 Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves
2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period
2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the Atopic Dermatitis Pipeline
2.5 What Do Physicians Think?
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for Atopic Dermatitis (20172027)
5.5.1 One-Year Total Prevalent Cases of Atopic Dermatitis
5.5.2 Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis
5.5.3 Sex-Specific One-Year Total Prevalent Cases of Atopic Dermatitis
5.5.4 One-Year Total Prevalent Cases of Atopic Dermatitis by Severity
5.5.5 One-Year Diagnosed Prevalent Cases of Atopic Dermatitis
5.5.6 Age-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis
5.5.7 Sex-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis
5.5.8 One-Year Diagnosed Prevalent Cases of Atopic Dermatitis by Severity
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Disease Management
6.1 Diagnosis and Treatment Overview
7 Competitive Assessment
8 Unmet Needs and Opportunity Assessment
8.2 Topical Treatments Without Side Effects
8.3 A Drug that Effectively Controls Patients’ Pruritus
8.4 Addressing Heterogeneity in the Pathophysiology of Atopic Dermatitis
8.5 Improved Patient Compliance and Education
9 Pipeline Assessment
9.2 Promising Drugs in Clinical Development
10 Current and Future Players
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 LEO Pharma
10.3.6 Eli Lilly
10.4 Other Players
11 Market Outlook
11.1 Global Markets
11.1.2 Drivers and Barriers - Global Issues
- LEO Pharma
- Eli Lilly
- Bausch Health
For more information about this report visit https://www.researchandmarkets.com/r/mc91nd
View source version on businesswire.com:https://www.businesswire.com/news/home/20190520005380/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs,Dermatological Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/20/2019 08:05 AM/DISC: 05/20/2019 08:05 AM